Arrowhead Pharmaceuticals Inc. (ARWR:NASDAQ) recently hosted a webinar going over its pulmonary programs. Read on to see why an H.C. Wainwright & Co. analyst believes the company is underappreciated by investors.
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price.
"The advent of NIAGEN IV could usher in a powerful new tailwind for revenue growth at ChromaDex Corp. (CDXC:NASDAQ)," noted an H.C. Wainwright & Co. report.
Bio-Path Holdings Inc. (BPTH:NASDAQ) recently announced its progress in its cancer clinical trials and plans to begin preclinical obesity studies, according to a Roth MKM research note.
"Along with the significantly lower pill burden compared to other phosphate binders, we believe the superior tolerability may be attributable to OLC's nanoparticle technology," noted an H.C. Wainwright & Co. research note, regarding Unicycive Therapeutics Inc.'s (UNCY:NASDAQ) trial of oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients.
Zevra Therapeutics Inc. (ZVRA:NASDAQ) recently presented positive final results from its Phase 2 trial evaluating KP1077 in idiopathic hypersomnia (IH) patients at the SLEEP 2024 conference, according to a Roth MKM research note.
According to a Canaccord Genuity research note, Verona Pharma Plc. received a US$650 million strategic financing, which management believes will extend the cash runway beyond 2026 and fund the upcoming commercial activities related to the potential FDA approval of ensifentrine.
Verona Pharma Plc. is well positioned to launch its ensifentrine into the substantial market of nearly 9 million COPD patients, according to a BTIG Research note.
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note.
